Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMoCC-SCD
NCT06002477Phase 1Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mecamylamine (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Peak P1 amplitude for Orienting trials of the Attention Network Test (ANT) at 72 hours. Started Jun 2025; status: recruiting.
02
Drugs
mecamylamine
Beyond the preview
Go deeper on NCT06002477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06002477.